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Mucopolysaccharidosis (MPS) IIIB is characterized by mild somatic features and severe neuro-
logical diseases leading to premature death. No definite treatment is available for MPS IIIB
patients. We constructed two recombinant adeno-associated virus (rAAV) vectors containing the
human a-N-acetylglucosaminidase (NaGlu) cDNA driven by either a CMV or a neuron-specific eno-
lase (NSE) promoter. In vitro, these rAAV vectors mediated efficient expression of recombinant
NaGlu in human MPS IIIB fibroblasts and mouse MPS IIIB somatic and brain primary cell cultures.
The secreted rNaGlu was taken up by both human and mouse MPS IIIB cells in culture and
degraded the accumulated glycosaminoglycans (GAG). A direct microinjection (107 viral parti-
cles, 1 ml/10 minutes per injection) of vectors containing the NSE promoter resulted in long-term
(6 months, the duration of the experiments) expression of rNaGlu in multiple brain struc-
tures/areas of adult MPS IIIB mice. Consistent with previous studies, the main target cells were
neurons. However, while vector typically transduced an area of 400–500 mm surrounding the infu-
sion sites, the correction of GAG storage involved neurons of a much broader area (1.5 mm) in
a 6-month duration of experiments. These results provide a basis for the development of a treat-
ment for neurological disease in MPS IIIB patients using AAV vectors.
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Mucopolysaccharidosis (MPS) IIIB (Sanfilippo syndrome
IIIB) is an inherited lysosomal storage disorder caused by
deficiency of a-N-acetylglucosaminidase (NaGlu). NaGlu
deficiency causes intracellular lysosomal accumulation of
the glycosaminoglycan (GAG) heparan sulfate. The dis-
ease is characterized by multiple organ/system involve-
ment and severe neurological degeneration [1].
Neurological deterioration occurs in most patients by 6 to
10 years of age with rapid and progressive retardation of
social and adaptive abilities leading to premature death.
No definite treatment is available for patients with MPS
IIIB. Therapy is limited to management of complications.
Bone marrow transplantation has been shown to be 
beneficial in MPS I [2,3]. So far, bone marrow transplan-
tation has not been shown to correct the central nervous
system (CNS) disease in MPS III patients. The success of
long-term enzyme replacement in MPS I offers promise
for the treatment of somatic disease in MPS [4]. However,42new treatment approaches are needed to restore NaGlu
activity in the CNS, and to prevent and control the neu-
rological degeneration in MPS IIIB patients.
The genomic structure of NaGlu has been identified
and the cDNA encoding NaGlu has been isolated [5,6]. A
mutant mouse model for MPS IIIB has been generated [7],
which provides a tool for developing novel therapies and
studying the precise process of the disease.
The adeno-associated virus (AAV) is a widespread par-
vovirus having no known associated pathology in human,
although most human tissues are susceptible to the virus
[8]. In the recombinant AAV (rAAV) vector system, 96%
of the viral genome is removed, leaving only the cis ter-
minal repeats that mediate DNA replication and packag-
ing [9,10]. In vivo rAAV-mediated gene transfer has resulted
in long-term and efficient gene expression in many tissues,
including muscle, lung, liver, retina, and CNS [11–19].
Previous studies have shown the expression of b-glu-
curonidase (GUSB) and the correction of GAG storage inMOLECULAR THERAPY Vol. 5, No. 1, January 2002
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rAAV vectors encoding human GUSB [5,20,21].
Here, we constructed AAV vectors containing human
NaGlu (hNaGlu) coding sequence cDNA, and driven by a
cytomegalovirus (CMV) promoter or a neuron-specific
enolase (NSE) promoter (Fig. 1). To investigate the feasi-
bility of AAV-mediated gene therapy for the neurological
disease in MPS IIIB using a mutant mouse model, we deliv-
ered the viral vectors into different brain structures/areas
of adult MPS IIIB mice by direct microinjection. Analysis
of vector-treated animals demonstrated AAV-mediated
expression of recombinant NaGlu and the correction of
GAG accumulation in mouse brain for 6 months (the dura-
tion of the experiments).
FIG. 1. Schematic diagram of recombinant AAV vectors. ITR, inverted termi-
nal repeat of AAV; CMV, human cytomegalovirus immediate early promoter;
NSE, neuron-specific enolase promoter; hNaGlu, human a-N-acetylglu-
cosaminidase cDNA; splic, SV40 splicing site; PA, SV40 polyadenylation site;
EGFP, enhanced green fluorescent protein gene.RESULTS
Expression and Secretion of Functional 
rNaGlu in Vitro
To test AAV-mediated gene therapy for MPS
IIIB, we generated AAV-NaGlu viral vectors
and infected both human MPS IIIB fibroblasts
and/or MPS IIIB mouse brain primary cell 
cultures (50–100 viral particles/ml in growth
medium). NaGlu activity above the level of
that in normal human (7.1 U/mg protein in
cells, 3.6 U/ml in medium) was detected in
the cell lysates (14 U/mg protein) as well as
in the medium (6.0 U/ml) of human MPS IIIB
fibroblasts transduced with AAV-CMV-
hNaGlu (Table 1). MPS IIIB mouse brain 
primary cell cultures transduced with MOLECULAR THERAPY Vol. 5, No. 1, January 2002
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the cells (3.7 U/mg protein) and in medium (1.6 U/ml;
Table 1) than that in the cells (1.2 U/mg protein) and
medium (1.2 U/ml) of normal mouse brain cells. The
NaGlu activity was also expressed in both the cells (1.2
U/mg protein) and the medium (1.0 U/ml) of MPS IIIB
mouse brain primary cell cultures when infected with
AAV-NSE-hNaGlu vectors, and was higher than that in
normal mouse brain cell cultures (Table 1). The enzyme
activity persisted at the same levels for the 5-week dura-
tion of the experiments in AAV-transduced MPS IIIB
mouse brain primary cell cultures.
FIG. 2. Uptake of 35SO4 in human skin fibroblast cell cultures. N, normal fibrob-
lasts; M, MPSIIIB fibroblasts; CMV, infection with AAV-CMV-hNaGlu; rN, incu-
bation with rNaGlu; 2.0U, 2.0 U/ml; 1.0U, 1.0 U/ml; 0.5U, 0.5 U/ml; 0.25,
0.25 U/ml, in the medium of transduced MPS IIIB cells; filled square, 72 hour
labeling; open square, 24 hours after the removal of the labeling medium. The
amount of rNaGlu added to the medium is based on NaGlu activity, expressed
as unit (U)/ml: 1 U = 1 nmol 4MU released/hour. n = 4.TABLE 1: AAV2-mediated in vitro NaGlu gene expression in human 
MPS IIIB fibroblasts and MPS IIIB mouse brain primary cell cultures
Cells Vector n aNaGlu activity 
cellular medium
GM00969D none 4 7.1 ± 0.18 3.6 ± 0.17
GM02931 none 4 0.0 0.3 ± 0.0
CMV 4 14.0 ± 0.32 6.0 ± 0.22
B+/+ none 3 0.9 ± 0.08 1.2 ± 0.13
B-/- none 3 0.0 0.3 ± 0.08
CMV 3 3.7 ± 0.16 1.6 ± 0.16
NSE 3 1.2 ± 0.08 1.0 ± 0.14
aThe NaGlu activities were means ± SD (standard deviation). NaGlu activity was expressed as
U/mg protein for cellular samples or U/ml for medium samples: 1U = 1 nmol of 4MU
released/hour or 1 U/ml = 1 nmol of 4MU released/hour.43
ARTICLE doi:10.1006/mthe.2001.0514, available online at http://www.idealibrary.com on IDEALIntracellular and Extracellular Activity of AAV-
Mediated rNaGlu
We carried out 35SO4-labeling experiments to study the cor-
rection of GAG storage in MPS IIIB cell cultures by AAV-
mediated rNaGlu. The accumulation of 35SO4-labeled mate-
rials in cultured human normal and MPS IIIB fibroblasts,
with or without the presence of the AAV-mediated rNaGlu,
is summarized in Fig. 2. In corporation of 35SO4 in human
MPS IIIB fibroblasts decreased 65%, to the level of that in
normal cells, when infected with AAV-CMV-hNaGlu, indi-
cating that the recombinant enzyme degraded the sulfated
materials in these cells. Human MPS IIIB fibroblasts incor-
porated 84%, 59%, or 49% less 35SO4, respectively, com-
pared with untreated cells, when incubated with medium
containing 2.0 U/ml, 1.0 U/ml, or 0.5 U/ml of rNaGlu
secreted by AAV-CMV-hNaGlu transduced MPS IIIB cells.
When treated with only 0.25 U/ml of rNaGlu, the decrease
of 35SO4 incorporation in human MPSIIIB fibroblasts was
11% (rNaGlu activity needed to achieve half-maximal cor-
rection was 0.6 U/ml in medium). Twenty-four hours after
withdrawal of 35SO4 from the medium, MPS IIIB cells 
transduced with AAV vectors or treated with rNaGlu 
displayed 60–90% reduction in 35SO4-labeled materials, 
A
C
44similar to normal cells (74%), whereas the reduction was
only 32% in nontreated MPS IIIB cells. These data demon-
strate that the secreted rNaGlu can be taken up by MPS IIIB
cells and is capable of degrading GAG.
Similar results were obtained working with mouse brain
primary cell cultures (Fig. 3A). The 35SO4 incorporation
decreased 71% in AAV-CMV-hNaGlu transduced MPS IIIB
mouse brain cells to the level of that seen in normal mouse
brain cell cultures. The decrease for AAV-NSE-hNaGlu trans-
duced MPS IIIB mouse brain cells was 33% compared with
that in nontransduced MPS IIIB mouse brain cells. In MPS
IIIB mouse kidney primary cell cultures, the transduction
with AAV-CMV-hNaGlu reduced the 35SO4 incorporation
by 71% to the normal level, and secreted rNaGlu (1.5 U/ml)
decreased 35SO4 incorporation by 40% (Fig. 3B) compared
with that in nontreated MPS IIIB cells.
We also conducted 35SO4 labeling using MPS IIIB pri-
mary liver and skin fibroblast cell cultures in the presence
of native human NaGlu (from HeLa cells) or native mouse
NaGlu (from mouse A9 cells), to determine whether the
species difference affected the uptake of the enzyme and
the function of NaGlu in the cells. It was shown that both
human and mouse NaGlu (2–3 U/ml in the medium) were
taken up by the mouse primary liver and skin fibroblasts
and reduced the accumulation of 35SO4 in the cells to a
similar level (Fig. 3C).
In Vivo Expression of Functional rNaGlu
Both AAV-CMV-hNaGlu and AAV-NSE-hNaGlu vectors
were microinjected into the inferior colliculus of MPS IIIB
mice (0.1 ml/min, 1 ml/site/injection, 107 viral particles/ml).
FIG. 3. Uptake of 35SO4 in mouse primary cell cultures. B, brain cells; K, kid-
ney cells; L, liver cells; +/+, normal cells; -/-, MPS IIIB cells; CMV, transduced
with AAV-CMV-hNaGlu; NSE, transduced with AAV-NSE-hNaGlu; rN, incu-
bated with the secreted rNaGlu (2.0 U/ml) in the medium of transduced MPS
IIIB cells; mM, incubated with the medium containing mouse native NaGlu
(2.0 U/ml) secreted by mouse A9 cells; hM, incubated with the medium con-
taining human native NaGlu (2.0 U/ml) secreted by HeLa cells. The amount
of NaGlu added to the medium is based on NaGlu activity expressed as unit
(U)/ml: 1U = 1 nmol 4MU released/hour. n = 4.
B
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IIIB mutant mice after microinjection of rAAV vectors
Brain n Vectors Weeks               bNaGlu activity
sample (pi)            range              mean
Normal 4 none 0.6–1.0 0.9
MPS IIIB 4 none 0.0 0.0
IC 4 CMV 4 3.6–96.7 9.4
IC 1 CMV 12 26.8
IC 2 NSE 4 93.5–98.6 96.0
IC 4 NSE 12 11.7–56.4 27.2
HIP 7 NSE 4 3.1–51.4 11.6
HIP 9 NSE 12 1.1–49.1 41.5
HYT 5 NSE 4 5.9–149.5 14.6
HYT 7 NSE 12 15.5–82.9 56.6
CTX-1a 1 NSE 4 0.7
-2 2.7
-3 2.8
CTX-1a 4 NSE 12 0.1–0.3 0.2
-2 0.2–3.6 1.3
-3 0.5–8.0 2.2
THL-1a 4 NSE 4 3.2–4.3 3.8
-2 0.2–0.5 0.3
aThese samples were divided into 2–3 sections due to relatively larger sizes and each 
section was assayed for NaGlu activity individually.
bNaGlu activity was expressed as U/mg protein: 1U = 1 nmol of 4MU released/hour.AAV-NSE-hNaGlu was also injected into four other brain
structures/areas of MPS IIIB mice: hippocampus, hypo-
thalamus, cerebral cortex, and thalamus. These vectors
mediated efficient rNaGlu expression in all injected brain
structures that persisted for the 12-week duration of the
experiments. In total, 48 mice were injected and analyzed
(Table 2). The injected cortices and thalamic areas demon-
strated relatively lower NaGlu activities, due to the rela-
tively larger size of these structures compared with infe-
rior colliculus, hippocampus, and hypothalamus. They
were therefore divided into two or three sections, which
were assayed for the NaGlu activity separately. The sec-
tions closer to the injection sites demonstrated higher
enzyme activities (Table 2).
AAV Tropism for Neurons
We used two vectors expressing enhanced green fluores-
cent protein (EGFP), AAV-CMV-EGFP and AAV-NSE-EGFP
(Fig. 1), to visualize the distribution of AAV-mediated gene
expression in mouse brain after microinjection. Results from
these experiments help model AAV-hNaGlu gene transfer
and expression that we observed in prior experiments (Fig.
4). When 1 ml (107 particles) of AAV-NSE-EGFP viral vectorMOLECULAR THERAPY Vol. 5, No. 1, January 2002
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week-old mice, EGFP was detected, 4 weeks after infu-
sion, in the neurons (including large multipolar neu-
rons) of the injected inferior colliculus, hippocamus,
hypothalamus, cortex, and thalamus (Figs. 4B–4F).
No obvious decrease in EGFP expression was
observed after the 3-month duration of the experi-
ments, supporting long-term expression, as previ-
ously described with these vectors. EGFP presented
throughout neuron cell bodies, in an area of 400–500
mm surrounding the infusion site, and in axons far-
ther away from the injection site, some of which
even extended to some areas on the contralateral side
of the brain. The AAV-CMV-EGFP vector resulted in
similar expression (data not shown) in these brain
sites 4 weeks after injection (longer observation with
this vector was not done). Consistent with previous
observations [12,13,18], no obvious sign of toxico-
logical reaction was observed in the injected mice
and no apparent cell damage was found in the areas
of the recombinant gene expression following the
delivery of AAV vectors by a single microinjection.
Correction of Lysosomal Storage in MPS IIIB
Mouse Brain
To study AAV-mediated correction of lysosomal
storage in MPS IIIB mouse brain, 1 ml of AAV-NSE-
hNaGlu vectors (107 viral particles/ml) was injected
into the thalamus (Franklin and Paxnos coordi-
nates: Bregma –2.0 mm, lateral right 1.2 mm, down
3.0 mm) over a period of 10 minutes. The animals
(four per experimental group) were sacrificed at 3
and 6 months after the injection, and cryostat brainsections were stained with toluidine blue. An obvious
decrease in the number and the sizes of swelling lysosomes
was observed in the neurons of thalamic nuclei on the
injected sides of MPS IIIB mouse brains, compared with
that in their contralateral structures (Fig. 5). The decrease
of lysosomal storage occurred in the areas approximately
1.5 mm surrounding the injection site and persisted at
least 6 months after microinjection. No obvious decrease
of lysosomal storage in the neurons in the noninjected
contralateral area was observed, compared with that of
noninjected MPS IIIB mouse brains.
DISCUSSION
The rAAV therapeutic vectors used in this study contain
only minimal regulatory elements required for NaGlu gene
expression genes (Fig. 1). We demonstrated that these AAV
viral vectors successfully delivered a human NaGlu gene
in vitro into human MPS IIIB fibroblasts and MPS IIIB
mouse brain primary cell cultures, and mediated above-
normal levels of rNaGlu expression. The AAV-mediated
recombinant NaGlu is functional and secreted. The
secreted enzyme can be taken up by both human and45
ARTICLE doi:10.1006/mthe.2001.0514, available online at http://www.idealibrary.com on IDEALFIG. 4. EGFP expression in different structures/sites of mouse brains after a single injection of AAV-NSE-EGFP. (A) Nontransduced cerebral cortex. (B) Inferior
colliculus. (C) Hippocampus. (D) Hypothalamus. (E) Cerebral cortex. (F) Thalamus.
A B C
D E Fmouse MPS IIIB somatic cells and mouse brain cells in
vitro, resulting in the correction of GAG accumulation in
the cells using only minimal amounts of enzyme (0.5–2.0
U/ml in the medium). It is consistent with previous stud-
ies that only very low levels (0.1–10% of normal) of lyso-
somal enzymes are needed to maintain normal cell func-
tion [22–26]. This suggests that expression and secretion
of hNaGlu mediated by rAAV may meet therapeutic needs
in deficient cells exposed to the enzyme.
The full-length human NaGlu cDNA was also success-
fully delivered into multiple sites/areas of adult MPS IIIB
mouse brain using rAAV viral vectors. These vectors,
driven by a NSE promoter, mediated efficient long-term
expression of enzymatically active recombinant human
NaGlu in all injected mouse brain structures/areas. In
mouse brain, the main target cells of AAV vectors seem to
be neurons. Using AAV-EGFP reporter vectors, we observed
that the transduction after microinjection was limited to
the neurons surrounding the injection sites within the
injected structures/areas. However, a long-term (6-month
duration of the experiments) correction of lysosomal stor-
age in a larger area, a bystander effect, was achieved by a
single injection in the MPS IIIB mouse brain. This suggests
that in vivo correction of GAG storage in MPS IIIB mouse
brain does not require transducing all deficient cells. We
anticipate that MPS IIIB mouse brain cells transduced by46AAV viral vectors can produce and secrete rNaGlu persist-
ently in vivo. The secreted rNaGlu may then defuse
through brain tissue, be taken up by surrounding neurons,
and play the role of degrading accumulated heparan sul-
fate, not only in transduced cells but also in non-trans-
duced neighboring cells, thus preventing further GAG stor-
age. In addition, we have observed by electron microscopy
that enlarged lysosomes are present in axons, while work-
ing with MPS II mouse brain samples (H.F., unpublished
data). This suggests that lysosomal enzymes may be trans-
ported from the neuronal cell body to distal areas of the
cell, through axons to the areas remote to the injection
sites, even possibly to the contralateral sphere of the brain.
In previous studies, complete reversion of lysosomal stor-
age lesions was observed in most neurons in broad brain
areas after a single injection of AAV viral vector into the
striatum [14] or cerebral cortex [17] of adult MPS VII mice.
Pathological changes of lysosomal storage in the MPS
IIIB mouse brain are ubiquitous under the light micro-
scope. However, the morphology of the aberrant storage
varies and can be difficult to visualize in the neurons in
some brain areas (H.F., unpublished data). The thalamus
is a relatively large structure and exhibits the typical micro-
scopic pathology of lysosomal storage, enlarged lysosomes
in the cytoplasm of the neurons in most thalamic nuclei
of MPS IIIB mouse brain. Therefore it is an ideal model areaMOLECULAR THERAPY Vol. 5, No. 1, January 2002
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(A), ventral posteromed thalamic nuclear (C), and red nuclear (E) of injected thalamus, and their non-injected counterlateral nuclei (B, D, and F). The arrows







for studying the correction of lysosomal storage in the
CNS of MPS IIIB mice, using light microscopy.
Previous studies showed that intrathecal and intra-
venous delivery of AAV vectors containing a m-glu-
curonidase gene into neonatal MPS VII mice resulted in
the complete correction of GAG storage in the CNS, which
carried to their adulthood [15,16,27]. However, in human
the blood–brain barrier is closed before birth. Like other
lysosomal enzymes, peripheral administered NaGlu would
not be expected to cross the blood–brain barrier.
Intravenous delivery of AAV vectors to the brain of
patients with MPS would require disruption of the
blood–brain barrier. We demonstrated here that direct
delivery of the human NaGlu gene into adult MPS IIIB
mouse brain can restore the NaGlu function in the injected
and a limited neighboring area, by single injection of 1 ml
of AAV vectors.
Our study also demonstrated that uptake of NaGlu is
not species-specific and that both human and mouse
NaGlu can efficiently catabolize the GAG accumulated in
MPS IIIB mouse primary cell cultures. It supports the use
of the MPS IIIB mutant mouse model as a tool for thera-
peutic studies of human MPS IIIB.MOLECULAR THERAPY Vol. 5, No. 1, January 2002
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for gene therapy studies on neurological disorders of
human MPS. Our studies suggest that recombinant AAV
vectors can successfully deliver the NaGlu gene and restore
the NaGlu activity in the CNS of adult MPS IIIB mice.
However, more efficient means to obtain global brain
delivery of the AAV viral vectors need to be developed.
MATERIALS AND METHODS
Construction of AAV-NaGlu expression plasmids. A plasmid containing
human NaGlu coding sequence cDNA (pCMVhuNAGLU) was provided by
Elizabeth F. Neufeld (UCLA). Two AAV serotype 2 (AAV2) derived plas-
mids, pTR-UF5 (containing a CMV promoter) and pTR-UF4 (containing a
NSE promoter), were obtained from Nicholas Muzyzcka (University of
Florida). A plasmid containing EGFP (pEGFP-N1) was obtained from
Clontech.
Two AAV2 viral vector plasmids expressing hNaGlu have been con-
structed in our laboratory. A 2.5-kb EcoRI fragment of pCMVhuNAGLU,
hNaGlu coding sequence cDNA, was inserted into the 4.2-kb NotI-SalI frag-
ment of pTR-UF5 or the 5.4-kb HindIII-NotI fragment of pTR-UF4 by blunt-
end ligation, to construct pAAV-CMV-hNaGlu and pAAV-NSE-hNaGlu
respectively.
Similarly, the pAAV-NSE-EGFP plasmid was constructed in our labo-
ratory by blunt-end ligation of the EGFP gene, a 0.7-kb Bsp120I-NotI frag-
ment of pEGFP-N1 (Clontech, 6085-1), with HindIII-NotI fragment of pTR-47
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McCarty (Gene Therapy Center, University of North Carolina at Chapel
Hill). These EGFP vectors were used to visualize AAV-mediated gene expres-
sion as a model for the expression of recombinant NaGlu (rNaGlu).
Production of rAAV viral vectors. The AAV viral vectors were produced
in HEK293 cells using cotransfection and purified using heparin affinity
chromatography by the Vector Core Facility, UNC Gene Therapy Center,
following published methods [28].
These viral vectors contain either the hNaGlu or the EGFP gene, and
the AAV2 terminal repeats, SV40 splice donor/acceptor, and SV40
polyadenylation (poly(A)) signals, driven by either a CMV or a NSE pro-
moter. The structures of these AAV viral vectors are illustrated in Fig. 1.
Animals. The heterozygous breeding pairs (F2) of the MPS IIIB knockout
mouse were provided by Elizabeth F. Neufeld (UCLA) [7]. The mice were
bred on an inbred background by backcrosses of heterozygotes and main-
tained in the Laboratory Animal Facility of University of North Carolina
at Chapel Hill. All the procedures were approved by IACUC at the univer-
sity. All care and procedures were in accordance with the Guide for the Care
and Use of Laboratory Animals (DHHS Publication No. (NIH) 85-23). The
progeny mice were identified by PCR amplification of a 300-bp fragment
of hNaGlu exon 6 and a 480-bp fragment of the neomycin gene.
Cell and tissue cultures. A human normal fibroblast cell line (GM00969D)
and a human MPS IIIB fibroblast cell line (GM02931) were obtained from
the NIGMS Human Genetic Mutant Cell Depository, NJ. They were grown
at 378C in MEM medium containing 10% fetal bovine serum (FBS).
Normal and MPS IIIB mouse brain primary cell cultures were generated
using published methods [29]. Neonatal mice less than 24 hours old were
identified by PCR as mentioned above and anesthetized with 2.5% Avertin
(0.38–0.43 mg/g body weight). The cortices were collected using sterile
procedures and used as the source of brain primary cell cultures. The cells
were incubated at 37°C in growth medium (DMEM containing 10% FBS).
Similarly, normal and MPS IIIB mouse liver, kidney, and skin fibrob-
last primary cell cultures were also generated based on published procedures
[30]. The liver, kidney, and skin tissues were collected using sterile proce-
dure, dissected into the size of 1 cm3 and rinsed with PBS (pH 7.2). The
cells were dissociated using 0.25% trypsin at 378C and filtered through a
cell strainer. The cells were incubated at 378C in growth medium (DMEM
containing 10% FBS). The cells were mixed cell types.
Infection of MPS IIIB cells with AAV viral vectors. To study the AAV-
mediated in vitro expression and secretion of rNaGlu, AAV-CMV-hNaGlu
viral vectors (50–100 viral particles/cell in growth medium) were used to
infect human MPS IIIB fibroblasts (on P-100 plates in 10 ml medium) and
MPS IIIB mouse primary brain cell cultures (on P-60 plates in 5 ml medium).
AAV-NSE-hNaGlu viral vectors were only used to infect MPS IIIB mouse
brain primary cell cultures. The cells and the medium were collected and
assayed for NaGlu activity after incubation at 378C for 48 hours for human
fibroblasts and 72 hours for mouse brain cell cultures. The harvested
medium containing rNaGlu was stored at –208C before being used in exper-
iments for the correction of GAG storage in MPS IIIB cells. Normal human
fibroblasts, normal mouse brain primary cell cultures, non-transduced MPS
IIIB human fibroblasts, and MPS IIIB mouse brain primary cell cultures
were used as controls. The FBS used in the experiments was incubated at
568C for 6 hours, to inactivate the high level of bovine NaGlu in the serum.
Direct microinjection of AAV vectors into the brain of MPS IIIB mice.
The stereotaxic (KOPF) microinjection was carried out following published
techniques [18], using coordinates from a mouse brain atlas [31]. The mice
at age 4 weeks were anesthetized with 2.5% Avertin (0.38–0.43 mg/g body
weight) and 1 ml AAV viral vectors (107 particles/ml) were infused at a rate
of 0.1 ml/min into brain tissues. The viral vectors were always injected into
the right-side brain structures, one injection per site per mouse, four mice
per experimental group. The injected brain structures were inferior col-
liculus, hippocampus, hypothalamus, cortex, and thalamus.
The mice, transduced with either AAV-CMV-hNaGlu or AAV-NSE-
hNaGlu, were anesthetized with 2.5% avertin and sacrificed at 4 and 12
weeks after injection. The injected brain compartments as well as con-
tralateral structures were collected and assayed individually for NaGlu activ-
ity. The whole brain samples were frozen on dry ice in OCT compound and48stored at –808C for histopathology studies. Samples of normal and non-
injected MPS IIIB mouse brain structures were used as controls.
AAV-CMV-EGFP and AAV-NSE-EGFP were also microinjected into the
above brain sites of MPS IIIB mice using the same technique, to visualize
AAV-mediated gene expression in mouse brain. Four weeks after AAV-vec-
tor infusion, the mice were anesthetized with 2.5% Avertin and perfused
transcardially with cold 0.1 M phosphate buffered saline (PBS, pH 7.4), fol-
lowed by 4% paraformaldehyde in phosphate buffer (0.1 M, pH 7.4). After
being fixed in 4% paraformaldehyde overnight, the brains were sectioned
(50 mm) using a vibratome. The sections were rinsed with PBS before being
mounted on slides and visualized with a fluorescent microscope.
NaGlu enzyme activity assay. The NaGlu enzyme activity was assayed
following a published method [32]. The tissue samples were homogenized
with a motor-driven pestles before being suspended in sample buffer (0.15
M NaCl containing 0.1% Triton X-100). The cell samples and homoge-
nized tissues were ruptured by freezing/thawing (on dry ice/at 378C) 3–5
times. The cell debris was discarded by centrifugation at 10,000 rpm.
Protein concentration of cells and tissue lysates were determined based on
the method of Bradford (Bio-Rad Protein Assay).
The enzyme assay measures 4-methylumbelliferone (4MU), a fluores-
cent product formed by hydrolysis of the substrate 4-methylumbellireyl-
N-acetyl-a-D-glucosaminide. The NaGlu activity is expressed as nmol of
4MU released/hour/mg protein for cellular samples and nmol of 4MU
released/hour/ml for medium and reported as unit (U): 1 U equal to 1 nmol
4MU released/hour.
35SO4 labeling of GAG in tissue cultures. 35SO4-labeling assay was carried
out in human fibroblasts and mouse primary brain cell cultures, as
described [32], to study the correction of GAG storage by AAV-mediated
expression of rNaGlu.
The experiments were carried out at least in triplicate. The cells were
grown on P100 tissue culture plates in Ham’s F-12 growth medium (10%
FBS, heat-inactivated at 568C for 6 hours) 48 hours before the addition of
35SO4. The medium was then replaced with labeling medium (F-12 growth
medium containing 4 mCi/ml of H235SO4, ICN), or labeling medium con-
taining AAV-CMV-hNaGlu, AAV-NSE-hNaGlu, rNaGlu secreted by human
MPS IIIB fibroblasts transduced with AAV-CMV-hNaGlu, natural human
NaGlu (from HeLa cells), or natural mouse NaGlu (from mouse A9 cells).
The 35SO4-labeled materials were measured in Ecoscint A scintillation fluid
and expressed as cpm/h/mg protein.
Histopathology. Histopathology was conducted following standard meth-
ods. The fresh whole brain samples of mice were embedded in OCT com-
pound and frozen on dry ice. Thin transverse sections (8 mm) were obtained
using a cryostat and fixed with 4% paraformaldehyde in phosphate buffer
(0.1 M, pH 7.2) at 48C for 15 minutes and stained with 1% toluidine blue,
which does not stain GAGs, at 378C for 30 minutes. The sections were
visualized under a light microscope.
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